| Статус: | Recruiting |
| Фаза: | N/A |
| Начало: | 1 мая 2018 г. |
| Окончание: | 31 августа 2024 г. |
| Описание: | This exploratory study aims to assess the efficacy, safety of the experimental treatment based on a combination of rituximab (RTX), intravenous (IV) cyclophosphamide (CYC), and corticosteroids (S) administrated at lower cumulative doses (RCP) for the induction of early remission in subjects with anti-PLA2R antibody-positive primary membranous nephropathy (PMN) having nephrotic syndrome (NS). |
| смотреть на ClinicalTrials.gov |